CSL Management

Management criteria checks 2/4

CSL's CEO is Gordon Naylor, appointed in Feb 2026, has a tenure of less than a year. total yearly compensation is $3.53M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth €9.91M. The average tenure of the management team and the board of directors is 2.3 years and 2.3 years respectively.

Key information

Gordon Naylor

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage	23.91%
CEO tenure	less than a year
CEO ownership	0.02%
Management average tenure	2.3yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gordon Naylor's remuneration changed compared to CSL's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2026	US$4m	US$844k	-US$3b

Compensation vs Market: Gordon's total compensation ($USD3.53M) is below average for companies of similar size in the German market ($USD5.87M).

Compensation vs Earnings: Insufficient data to compare Gordon's compensation with company performance.

CEO

Gordon Naylor (63 yo)

less than a year

Tenure

US$3,527,741

Compensation

Mr. Gordon Naylor, M.B.A., GradDip (Computing Studies), BEng (Hons), DipCompSc, C.P.A., GAICD, FTSE, MIE(Aust), serves as Chief Executive Officer and Managing Director at CSL Limited since February 2026. H...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gordon Naylor	CEO, MD & Director	less than a year	US$3.53m	0.020% € 9.9m
Ken Lim	Chief Financial Officer	less than a year	US$714.68k	no data
Mary Oates	Executive VP & COO	1.3yrs	no data	no data
Mark Dehring	Head of Investor Relations	no data	no data	no data
Gregory Boss	Executive VP of Legal & Group General Counsel	17.6yrs	US$2.31m	no data
Amy Buren	Chief People Officer	less than a year	no data	no data
William Mezzanotte	Chief Medical Officer	7.8yrs	US$2.14m	no data
Stephen Marlow	Executive VP & GM of CSL Plasma	less than a year	no data	no data
Mark Hill	Chief Digital Information Officer & Executive VP	5.8yrs	no data	no data
Herve Gisserot	Executive VP of Business Development & Enterprise Alliance Management	3.4yrs	no data	no data
Kate Priestman	Chief Corporate & External Affairs Officer	2.9yrs	no data	no data
Dave Ross	Executive VP & GM of CSL Seqirus	2.3yrs	no data	no data

2.3yrs

Average Tenure

61yo

Average Age

Experienced Management: CSJ's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gordon Naylor	CEO, MD & Director	less than a year	US$3.53m	0.020% € 9.9m
Alison Watkins	Independent Non-Executive Director	5yrs	US$265.09k	0.0014% € 698.1k
Carolyn Hewson	Independent Non-Executive Director	6.7yrs	US$249.63k	0.00081% € 401.0k
Brian McNamee	Independent Non-Executive Chairman	8.5yrs	US$640.23k	0.027% € 13.2m
Robert Cuthbertson	Independent Non-Executive Director	7.8yrs	US$234.25k	0.015% € 7.4m
Brian Daniels	Independent Non-executive Director	1.7yrs	US$236.75k	0.00018% € 89.1k
Cameron Price	Independent Non- Executive Director	less than a year	US$167.09k	no data
Samantha Lewis	Independent Non-executive Director	2.6yrs	US$205.63k	0.00049% € 242.6k
Constantine Saroukos	Independent Non-executive Director	less than a year	US$112.83k	no data
Elaine Sorg	Independent Non-Executive Director	1.9yrs	US$264.42k	no data

2.3yrs

Average Tenure

63yo

Average Age

Experienced Board: CSJ's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/22 08:40
End of Day Share Price	2026/08/21 00:00
Earnings	2026/06/30
Annual Earnings	2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSL Limited is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Saul Hadassin	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter
Lyanne Harrison	BofA Global Research

CSL Management

Management criteria checks 2/4

Key information

Recent management updates

CSL Limited, Annual General Meeting, Oct 27, 2026

High number of new directors

CSL Limited Announces Chief Executive Officer Changes

CSL Limited, Annual General Meeting, Oct 28, 2025

Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited

Independent Non-Executive Chairman recently sold €3.3m worth of stock

Recent updates

New minor risk - Share price stability

Final dividend of US$1.62 announced

CSL Limited Provides Earnings Guidance for the Year 2027

CSL Limited, Annual General Meeting, Oct 27, 2026

Full year 2026 earnings released: US$5.35 loss per share (vs US$6.20 profit in FY 2025)

Csl Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry in Children with Hereditary Angioedema

Investor sentiment improves as stock rises 18%

High number of new directors

CSL Limited Estimates Ordinary Dividend for the Six Months Period Ended December 31, 2025, Payable on April 9, 2026

CSL Limited Announces Chief Executive Officer Changes

CSL Announces Five-Year (60-Month) Results from the Pivotal Phase 3 Hope-B Study

Csl Limited Revises Earnings Guidance for Financial Year 2026

CSL Limited, Annual General Meeting, Oct 28, 2025

CSL Limited to Report First Half, 2026 Results on Feb 02, 2026

CSL Limited Announces Unfranked Dividend for the Period of Six Months Ended June 30, 2025, Payable on October 03, 2025

CSL Limited Provides Earnings Guidance for the Year 2026

Health Canada Authorized CSL's Andembry (Garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (Hae)

CSL Limited announces U.S. Food and Drug Administration Approves Csl's Andembry®? (Garadacimab-Gxii) Treatment Targeting Factor Xiia with Once-Monthly Dosing for All Patients from the Start

CSL Vifor Announces England's Nice Recommends Filspari®? (Sparsentan) as A Treatment Option for IgA Nephropathy

CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine

European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited

CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Now 20% undervalued

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Now 20% undervalued

Now 22% undervalued

Now 20% undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 22% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold €3.3m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

Now 21% undervalued after recent price drop

Independent Non-Executive Director recently bought €174k worth of stock

Non-Independent Non-Executive Director recently sold €4.3m worth of stock